Biofilms that form in the human body are up to ten thousand times more resistant to antibiotics than free-floating bacteria, making them very difficult to treat medically. These biofilms are responsible for the extreme persistence of many difficult to treat illnesses like Legionnaire’s disease, Staphylococcus aureus (“Staph”), and infectious bronchitis, that can trouble patients with frustrating symptoms for years.
Some years ago researchers showed that biofilms might also be helping the Lyme-causing bacteria evade treatment.(1) These findings have excited Lyme researchers who have since been exploring various treatment strategies designed to target the entire bacterial colony. If successful, these treatments might bring long-needed relief to patients with late-stage or persistent Lyme disease where antibiotics have previously failed.
At Bay Area Lyme Foundation, we are also inspired by these discoveries and hopeful about the treatment options they may bring. Recently we invited Daina Zeng, a Senior Scientist at Agile Sciences, to talk about the work her team is doing adapting Agile’s proprietary non-toxic organic compounds to disperse these bacterial colonies (technology they have leveraged for medical, agricultural, and industrial uses). Her post follows.